Feasibility of simple chitosan sheet as drug delivery carrier

Saito, Kieko; Fujieda, Takuya; Yoshioka, Hisashi

doi:10.1016/j.ejpb.2006.04.008

Cited by 13 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, glycol chitosan cannot be degraded in a normal solution. The simulation results in this section correspond well with experimental results from Saito et al [13], who reported that chitosan could be stable in a water solution but is degraded in an acidic solution, because H + in acid can more easily act on the GC-DOX bond than H 2 O can.…”

Section: Resultssupporting

confidence: 87%

Preliminary Study of Conformation and Drug Release Mechanism of Doxorubicin-Conjugated Glycol Chitosan, via cis-Aconityl Linkage, by Molecular Modeling

Srinophakun

Boonmee

2011

IJMS

View full text Add to dashboard Cite

An investigation of the structure and drug release mechanism of a drug delivery system is proposed on the basis of semi-empirical and ab initio computations in vacuum stage. Cis-aconityl linkage is used to improve the interaction between an anti-cancer agent, doxorubicin, and a glycol chitosan biopolymer. It has been found that the doxorubicin-conjugated glycol chitosan carrier has more stability. The stability is increased when the lengths of the polyethylene glycol (PEG) chains in the glycol chitosan biopolymer are increased. Cis-aconityl can release doxorubicin under appropriate environmental conditions. Relative energies of this mechanism in an acid condition, as determined by B3LYP/6-31G//PM3, are 122.41, 119.27, 160.18 and 222.22 kcal/mol, and by the B3LYP/6-31G//HF/6-31G method are 54.23, 109.28, 219.98 and 980.49 kcal/mol, with mono-, di-, tri-, and quanta-ethylene glycol, respectively. In a normal condition, the relative energies are above 300 kcal/mol for all reactions. Therefore, cis-aconityl will release doxorubicin in an acid solution but not in a normal condition. The glycol chitosan polymer can be degraded in an acid solution as well. Long PEG chains influence the release mechanism of doxorubicin. The proposed length of the PEG chain is di-ethylene glycol. These simulation results agree well with various reported experimental data.

show abstract

Section: Resultssupporting

confidence: 87%

Preliminary Study of Conformation and Drug Release Mechanism of Doxorubicin-Conjugated Glycol Chitosan, via cis-Aconityl Linkage, by Molecular Modeling

Srinophakun

Boonmee

2011

IJMS

View full text Add to dashboard Cite

show abstract

“…In their seminal study involving chitosan sheets, Saito et al [101] used a simple agglutination technique to develop pure flat, flexible chitosan sheets in order to explore the feasibility of chitosan as a drug carrier in topical lesions. Under phase-contrast microscopy, the sheet appeared as a knitted stitch with fine fibrous structure.…”

Section: Chitosan Sheets/filmsmentioning

confidence: 99%

Review: doxorubicin delivery systems based on chitosan for cancer therapy

Tan¹,

Choong²,

Dass³

2009

j pharm pharmacol

View full text Add to dashboard Cite

Objectives This review sheds insight into an increasingly popular polymer that has been widely explored as a potential drug delivery system. The abundant, biodegradable and biocompatible polysaccharide chitosan, with many other favourable properties, has been favoured as a drug delivery system for the purposes of encapsulating and delivery of doxorubicin with reduced side-effects. Key findings Doxorubicin is frequently used as a frontline chemotherapeutic agent against a variety of cancers. It has largely been able to demonstrate anti-tumour effects, though there are major shortfalls of doxorubicin, which include serious side-effects such as cardiomyopathy and myelosuppression, and also an ever-present danger of extravasation during drug administration. In view of this, drug delivery systems are currently being explored as alternative methods of drug delivery in a bid to more effectively direct doxorubicin to the specific lesion site and reduce its systemic side-effects. Liposomes and dendrimers have been tested as potential carriers for doxorubicin; however they are not the focus of this review. Summary Recent advancements in doxorubicin and chitosan technology have shown some preliminary though promising results for cancer therapy.

show abstract

“…Meanwhile, chitosan, as well as inhibiting fibroblasts, might directly inhibit the proliferation of RPE. Moreover, chitosan, due to its hyper-glutinousness and satisfactory slow-release characteristic, is a good drug-delivery carrier [2,22]. Thus, either applying chitosan alone or together with other antihyperplasty medicine in the vitreous cavity will play a role in inhibiting RPE and reducing the occurrence of PVR.…”

Section: Figmentioning

confidence: 99%

“…It is one of four generally accepted biomedical materials worldwide, which has good biocompatibility, biodegradability, antibiosis, hemostasis and promotion of peri-nerve regeneration. It can inhibit the proliferation of fibroblasts [1], and is an ideal drug delivery carrier [2]. Clinically, chitosan has been widely used in surgical operations on articular cavity, abdominal cavity and pelvic cavity, and satisfactory effectiveness has been obtained in preventing postoperative adherence.…”

Section: Introductionmentioning

confidence: 99%

Feasibility study of chitosan as intravitreous tamponade material

Yang

Wang

Gu³

et al. 2008

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Chitosan intravitreous tamponade has no significant effect on the histology of the eye, doesn't cause intraocular pressure to fluctuate, and slightly increases inflammatory factors (IL-6, IL-8, NO) in comparison to the normal levels, but with no significant difference from the effects caused by sodium hyaluronate, which indicated chitosan might not lead to a clinically significant inflammatory response. It suggests that chitosan could be used as intravitreous tamponade material.

show abstract

Feasibility of simple chitosan sheet as drug delivery carrier

Cited by 13 publications

References 20 publications

Preliminary Study of Conformation and Drug Release Mechanism of Doxorubicin-Conjugated Glycol Chitosan, via cis-Aconityl Linkage, by Molecular Modeling

Preliminary Study of Conformation and Drug Release Mechanism of Doxorubicin-Conjugated Glycol Chitosan, via cis-Aconityl Linkage, by Molecular Modeling

Review: doxorubicin delivery systems based on chitosan for cancer therapy

Feasibility study of chitosan as intravitreous tamponade material

Contact Info

Product

Resources

About